PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21913898-2	2012	This study assessed the effects of the PDE4 inhibitor roflumilast and its active metabolite, roflumilast N-oxide on the release of a range of chemokines (CCL2, 3, 4, CXCL1, 8, 10) and of TNF-alpha, from human lung macrophages, stimulated with bacterial lipopolysaccharide LPS.	n-oxide	105-112	C-C motif chemokine ligand 2	Homo sapiens	154-158	
33363471-6	2020	Results: At a clinically relevant concentration (1 nM), roflumilast N-oxide and roflumilast consistently reduced the release of TNF-alpha, CCL2, CCL3, CCL4, CCL5 and CXCL9 (but not CXCL1, CXCL5, CXCL8 and IL-6) from human bronchial explants.	n-oxide	68-75	C-C motif chemokine ligand 2	Homo sapiens	139-143	
21913898-8	2012	Roflumilast and roflumilast N-oxide concentration-dependently reduced the LPS-stimulated release of CCL2, CCL3, CCL4, CXCL10 and TNF-alpha from human lung macrophages, whereas that of CXCL1 or CXCL8 was not altered.	n-oxide	28-35	C-C motif chemokine ligand 2	Homo sapiens	100-104	
21913898-12	2012	CONCLUSIONS AND IMPLICATIONS: Roflumilast and roflumilast N-oxide reduced LPS-induced release of CCL2, 3, 4, CXCL10 and TNF-alpha in human lung macrophages.	n-oxide	58-65	C-C motif chemokine ligand 2	Homo sapiens	97-107